|
시장보고서
상품코드
1888599
심막 질환 시장 규모, 점유율, 동향 분석 보고서 : 약물 종류별, 질환 종류별, 유통 채널별, 지역별, 부문별 예측(2025-2033년)Pericardium Diseases Market Size, Share & Trends Analysis Report By Drug Class (NSAIDs, Colchicine), By Disease Type (Acute Pericarditis, Recurrent Pericarditis), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033 |
||||||
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
심막 질환 시장 : 개요
세계의 심막 질환 시장 규모는 2024년에 29억 6,000만 달러로 추정되며, 2033년까지 50억 6,000만 달러에 달할 것으로 예측됩니다.
2025년부터 2033년까지 6.14%의 CAGR을 기록할 것으로 예상됩니다. 이러한 성장은 심혈관질환의 유병률, 고령화, 진단 능력의 향상으로 인해 심막염, 심낭액 저류, 구속성 심막염과 같은 심막 질환에 대한 효과적인 치료법에 대한 수요가 증가하고 있습니다.
심장 관련 질환의 조기 발견 및 관리에 대한 인식이 높아짐에 따라 첨단 치료법 및 최소침습적 중재법 채택이 촉진되고 있습니다. 또한, 좌식 생활습관, 만성 감염, 자가면역질환, 수술 후 합병증 등의 요인도 질병 부담 증가에 기여하고 있습니다.
세계 심낭염 시장은 의료 관행의 발전, 생활 양식의 변화, 기술 혁신에 의해 주도되고 있습니다. 심낭의 염증을 특징으로 하는 심낭염은 심낭에 영향을 미치는 가장 흔한 질환입니다. 미국 국립의학도서관에 따르면 심낭증은 급성, 초기, 아급성, 만성, 재발형으로 분류되며, 전체 환자의 약 15-30%를 차지하는 것으로 추정됩니다. 고혈압, 자가면역질환, 감염, 심근경색 후 합병증 등 심혈관계 위험요인의 유병률 증가로 시장 기회가 확대되고 있습니다.
자주 묻는 질문
목차
제1장 분석 방법·범위
제2장 주요 요약
제3장 심막 질환 시장 : 변수, 동향, 범위
- 시장 연관 전망
- 시장 역학
- 사업 환경 분석
- 업계 분석 : Porter's Five Forces 분석
- PESTLE 분석
- 파이프라인 분석
제4장 세계의 심막 질환 시장 : 약물 종류별 추정·동향 분석
- 시장 점유율 : 약물 종류별(2024년·2033년)
- 시장 규모 예측과 동향 분석 : 약물 종류별(2021-2033년)
- 비스테로이드성 항염증제(NSAID)
- 콜히친
- IL-1β 억제제
- 코르티코스테로이드
- 면역억제제
- 기타
제5장 세계의 심막 질환 시장 : 질환 종류별 사업 분석
- 시장 점유율 : 질환 종류별(2024년·2033년)
- 시장 규모 예측과 동향 분석 : 질환 종류별(2021-2033년)
- 재발성 심막염
- 급성 심막염
- 구속성 심막염
제6장 세계의 심막 질환 시장 : 유통 채널별 사업 분석
- 시장 점유율 : 유통 채널별(2024년·2033년)
- 시장 규모 예측과 동향 분석 : 유통 채널별(2021-2033년)
- 병원 약국
- 소매 약국
- 온라인 약국
제7장 세계의 심막 질환 시장 : 지역별 사업 분석
- 시장 점유율 분석 : 지역별(2024년·2033년)
- 시장 대시보드 : 지역별
- 시장 규모 예측과 동향 분석(2021-2033년)
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- 아랍에미리트(UAE)
Pericardium Diseases Market Summary
The global pericardium diseases market size was estimated at USD 2.96 billion in 2024 and is projected to reach USD 5.06 billion by 2033, growing at a CAGR of 6.14% from 2025 to 2033. The growth is driven by the prevalence of cardiovascular conditions, aging populations, and improved diagnostic capabilities, which are driving demand for effective treatments targeting pericardial disorders such as pericarditis, pericardial effusion, and constrictive pericarditis.
Rising awareness about early detection and management of heart-related conditions is boosting the adoption of advanced therapeutics and minimally invasive interventions. Factors such as sedentary lifestyles, chronic infections, autoimmune diseases, and post-surgical complications have also contributed to the growing disease burden.
The global pericarditis market is driven by advancements in healthcare practices, evolving lifestyles, and technological innovation. Pericarditis, characterized by inflammation of the pericardial sac, remains the most prevalent pathological condition affecting the pericardium. According to the National Library of Medicine, pericardial cases are classified into acute, incipient, subacute, chronic, and recurrent forms, accounting for an estimated 15%-30% of cases. The increasing prevalence of cardiovascular risk factors, including hypertension, autoimmune disorders, infections, and post-myocardial infarction complications, is augmenting the market opportunity.
Global Pericardium Diseases Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pericardium diseases market report based on drug class, disease type, distribution channel, and region.
- Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Colchicine
- IL-1B Inhibitors
- Corticosteroids
- Immunosuppressant's
- Others
- Disease Type Outlook (Revenue, USD Million, 2021 - 2033)
- Recurrent Pericarditis
- Acute Pericarditis
- Constrictive Pericarditis
- Distribution Channel Outlook (revenue, USD Million, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Norway
- Sweden
- Denmark
- Asia Pacific
- China
- Japan
- India
- Australia
- Thailand
- South Korea
- Latin America
- Argentina
- Brazil
- Middle East & Africa
- Saudi Arabia
- South Africa
- Kuwait
- UAE
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Drug Class
- 1.2.2. Disease Type
- 1.2.3. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Global Pericardium Diseases Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. Global Pericardium Diseases Market: Drug Class Estimates & Trend Analysis
- 4.1. Drug Class Market Share, 2024 & 2033
- 4.2. Drug Class Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
- 4.4. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- 4.4.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5. Colchicine
- 4.5.1. Colchicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6. IL-1B Inhibitors
- 4.6.1. IL-1B Inhibitors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.7. Corticosteroids
- 4.7.1. Corticosteroids Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.8. Immunosuppressants
- 4.8.1. Immunosuppressants Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.9. Others
- 4.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Global Pericardium Diseases Market: Disease Type Business Analysis
- 5.1. Disease Type Market Share, 2024 & 2033
- 5.2. Disease Type Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Disease Type, 2021 to 2033 (USD Million)
- 5.4. Recurrent Pericarditis
- 5.4.1. Recurrent Pericarditis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Acute Pericarditis
- 5.5.1. Acute Pericarditis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6. Constrictive Pericarditis
- 5.6.1. Constrictive Pericarditis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Global Pericardium Diseases Market: Distribution Channel Business Analysis
- 6.1. Distribution Channel Market Share, 2024 & 2033
- 6.2. Distribution Channel Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
- 6.4. Hospital Pharmacies
- 6.4.1. Hospital Pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Retail Pharmacies
- 6.5.1. Retail Pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. Online Pharmacies
- 6.6.1. Online Pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Global Pericardium Diseases Market: Regional Business Analysis
- 7.1. Regional Market Share Analysis, 2024 & 2033
- 7.2. Regional Market Dashboard
- 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
- 7.4. North America
- 7.4.1. North America Pericardium Diseases Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Regulatory framework/ reimbursement structure
- 7.4.2.3. Competitive Scenario
- 7.4.2.4. Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Regulatory framework/ reimbursement structure
- 7.4.3.3. Competitive Scenario
- 7.4.3.4. Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Regulatory framework/ reimbursement structure
- 7.4.4.3. Competitive Scenario
- 7.4.4.4. Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Europe
- 7.5.1. Europe Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Regulatory framework/ reimbursement structure
- 7.5.2.3. Competitive Scenario
- 7.5.2.4. Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Regulatory framework/ reimbursement structure
- 7.5.3.3. Competitive Scenario
- 7.5.3.4. Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Regulatory framework/ reimbursement structure
- 7.5.4.3. Competitive Scenario
- 7.5.4.4. Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Regulatory framework/ reimbursement structure
- 7.5.5.3. Competitive Scenario
- 7.5.5.4. Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Regulatory framework/ reimbursement structure
- 7.5.6.3. Competitive Scenario
- 7.5.6.4. Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Norway
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Regulatory framework/ reimbursement structure
- 7.5.7.3. Competitive Scenario
- 7.5.7.4. Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.8. Sweden
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Regulatory framework/ reimbursement structure
- 7.5.8.3. Competitive Scenario
- 7.5.8.4. Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.9. Denmark
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Regulatory framework/ reimbursement structure
- 7.5.9.3. Competitive Scenario
- 7.5.9.4. Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. India
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Regulatory framework/ reimbursement structure
- 7.6.2.3. Competitive Scenario
- 7.6.2.4. Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Regulatory framework/ reimbursement structure
- 7.6.3.3. Competitive Scenario
- 7.6.3.4. Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. Japan
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Regulatory framework/ reimbursement structure
- 7.6.4.3. Competitive Scenario
- 7.6.4.4. Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Thailand
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Regulatory framework/ reimbursement structure
- 7.6.5.3. Competitive Scenario
- 7.6.5.4. Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.6. South Korea
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Regulatory framework/ reimbursement structure
- 7.6.6.3. Competitive Scenario
- 7.6.6.4. Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.7. Australia
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Regulatory framework/ reimbursement structure
- 7.6.7.3. Competitive Scenario
- 7.6.7.4. Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.8. Thailand
- 7.6.8.1. Key Country Dynamics
- 7.6.8.2. Regulatory framework/ reimbursement structure
- 7.6.8.3. Competitive Scenario
- 7.6.8.4. Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Regulatory framework/ reimbursement structure
- 7.7.2.3. Competitive Scenario
- 7.7.2.4. Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Regulatory framework/ reimbursement structure
- 7.7.3.3. Competitive Scenario
- 7.7.3.4. Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Regulatory framework/ reimbursement structure
- 7.8.2.3. Competitive Scenario
- 7.8.2.4. Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Regulatory framework/ reimbursement structure
- 7.8.3.3. Competitive Scenario
- 7.8.3.4. Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.4. Kuwait
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Regulatory framework/ reimbursement structure
- 7.8.4.3. Competitive Scenario
- 7.8.4.4. Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.9. UAE
- 7.9.1.1. Key Country Dynamics
- 7.9.1.2. Regulatory framework/ reimbursement structure
- 7.9.1.3. Competitive Scenario
- 7.9.1.4. Pericardium Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
샘플 요청 목록